CervoMed Announces Last Patient Last Visit In Phase 2b RewinD-LB Trial Of Neflamapimod For The Treatment Of Early-Stage Dementia With Lewy Bodies

Benzinga · 10/15 12:18

• On track to report topline data from the Phase 2b trial in December 2024

 

• Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients

• 96% of patients enrolled in RewinD-LB completed the 16-week portion of the study, of which 98% continued into the open label extension

BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced the Last Patient Last Visit in RewinD-LB, a Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB). CervoMed remains on track to report topline efficacy and safety data in December 2024.